COVID-19

 

HOVON:

We would like to inform you that the HOVON Data Center (HDC) and the HOVON Safety Desk will remain fully operational to ensure the safety of the patients included in HOVON trials.

The distribution and delivery of the study medicinal products are being closely monitored and we will inform you accordingly if any actions need to be taken.

The central laboratories are also still fully functioning.

At the moment it is possible to include patients in all active HOVON trials.

 

Participating sites:

Please make sure to inform the HOVON Data Center per e-mail (hdc@erasmusmc.nl) if your hospital has decided to temporarily halt patient inclusion in clinical trials following the COVID-19 outbreak.

In case patient visits or study procedures cannot be performed per protocol due to the COVID-19, please document this in the patient files.

 

Contact:

Given the situation surrounding the Corona virus, the HOVON central Office (HCB) and the HOVON Data Center (HDC) are temporarily unavailable by phone.

Please send all (urgent) question via email, these will be picked up and processed by the team as soon as possible. If you wish us to call you back, please indicate this in your message. We hope for your understanding of this situation.

For study specific questions, you can contact the concerning HOVON Trial Manager or our general e-mail address (hdc@erasmusmc.nl - Please include HOVON study number as reference). Thank you for your cooperation.

 

HOVON Central Office (HCB): hovonbureau@vumc.nl

HOVON Data Center (HDC): hdc@erasmusmc.nl

 

With kind regards, Marleen Breems (HOVON General Director) and Bianca Backx (manager HDC)


SLUITEN
sluit venster

Log in

Username Password Forgotten your user name and/or password? Want to request a user name and/or password?

Search in the HOVON website

Sitemap

 

The site map below provides an overview of the pages of the Hovon website. The pages that are only visible after login in are marked red. Please note that also study documents (except for the protocol) are only available after login in).

 

 

Page

Root

Intro

General

•  Welcome

•  About HOVON

• •  General

• •  Hovon central office

• •  Hovon data center

• •  Hovon Addresses

• •  Templates & docs

• •  Hovon policy documents

• • •  Protected policies

• •  HOVON Belgium

•  News and agenda

• •  News HOVON general

• •  Study News

• •  HOVON agenda

• •  News HDC

•  Links

Field of work

•  Medics

• •  About trials

• •  Treatment advice

• • •  ALL

• • •  AML

• • •  CLL

• • •  CML

• • •  MDS

• • •  MH

• • •  MM

• • •  NHL

• • •  Benigne

• • •  Supportive Care

•  Industry

•  Lokale data manager

Patients

•  Participation in trial

•  Links for patients

•  Medical information

• •  Introduction

• •  ALL

• •  AML

• •  CLL

• •  CML

• •  MDS

• •  MH

• •  MM

• •  NHL

• •  Benigne

• •  Supportive care

Trials

•  Trials (by type)

• •  ALL

• •  AML

• •  CLL

• •  CML

• •  MDS

• •  MH

• •  MM

• •  NHL

• •  Benign

• •  Supportive Care

•  Trials (all)

•  Trial search

•  General information about studies

• •  HOVON guidelines & documents

• •  Legislation

•  Study terms

Working groups

•  Working groups

• •  Myeloma

• • •  Guidelines Multipel Myeloom

• •  Leukemia

• • •  Guidelines CML

• • •  Guidelines ALL

• • •  Guidelines AML

• • •  Guidelines MDS

• • •  HOVON-SAKK minutes

• •  CLL

• • •  Guidelines CLL

• •  Lymfoma

• • •  Guidelines Lymfoma

• • • •  Pathology

• • • •  Staging and response criteria

• • • •  DLBCL

• • • •  FL

• • • •  MCL

• •  Stem cell transplantation

• • •  Guidelines for alloSCT

•  Technical commissions

• •  Network Molecular Diagnostics

• •  Working group stem cell laboratories Netherlands

• •  Hematology Review Commission

• •  Protocols Feasibility Commission (PUC)

Contact

•  HOVON general

•  HOVON Central Office

•  Hovon Data Center

•  HOVON Belgium

Help

•  Help with the website

•  Requesting HOVON and/or TOP logon
•       Site map

Search

News